Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07611214 · ClinicalTrials.gov registry record · Phase 4
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
A Phase 4 study, sponsored by Aurinia Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT07611214: Recruiting Phase 4 study, sponsored by Aurinia Pharmaceuticals.
NCT07611214 is a Phase 4 study that is actively recruiting participants, run by Aurinia Pharmaceuticals. The registered enrollment target is 150 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07611214, a Phase 4 study, is actively recruiting participants, sponsored by Aurinia Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
Interventions
- DRUG LUPKYNIS
- BIOLOGICAL belimumab, obinutuzumab or anifrolumab
- DRUG mycophenolic acid analog (MPAA)
- DRUG corticosteroid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-04-22 |
| Est. Completion | 2029-03-02 |
| Phase | Phase 4 |
What NCT07611214 shows while recruiting
NCT07611214 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 4 interventions - of which LUPKYNIS is the first listed.
NCT07611214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07611214 about?
NCT07611214 is a clinical study titled "PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis". The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
What is the current status of trial NCT07611214?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2026-04-22. Estimated completion is 2029-03-02.
What interventions are being tested in trial NCT07611214?
The interventions under investigation include: LUPKYNIS (DRUG), belimumab, obinutuzumab or anifrolumab (BIOLOGICAL), mycophenolic acid analog (MPAA) (DRUG), corticosteroid (DRUG).
Who is sponsoring clinical trial NCT07611214?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07611214's enrollment target sits among peer trials
150 533rd of 2000 higher than 1,436 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI